The Cancer Discovery editors proudly present this collection of impactful Clinical Trials articles that have been published in the Journal. Enjoy complimentary access for a limited time!
-
First-in-Human Trial of the Oral Ataxia Telangiectasia and Rad3-Related Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors
. -
Triplet therapy with palbociclib, taselisib and fulvestrant in PIK3CA mutant breast cancer and doublet palbociclib and taselisib in pathway mutant solid cancers
. -
Phase I trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 and non-BRCA1/2 mutant cancers
. -
Bempegaldesleukin (NKTR-214) Plus Nivolumab in Patients With Advanced Solid Tumors: Phase 1 Dose-Escalation Study of Safety, Efficacy and Immune Activation (PIVOT-02)
. -
Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers
. -
HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers
. -
Targeting HER2 with [fam-] trastuzumab deruxtecan: A dose-expansion, phase 1 study in multiple advanced solid tumors
. -
Acalabrutinib Plus Obinutuzumab in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia
. -
Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer
. -
Adenosine A2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer
. -
First-in-Human Phase I Study of BLU-554 Validates Aberrant Fibroblast Growth Factor 19 Signaling as a Driver Event in Hepatocellular Carcinoma
. -
Tumor genomic profiling guides metastatic gastric cancer patients to targeted treatment: The VIKTORY Umbrella Trial
. -
Combination Olaparib and Temozolomide in Relapsed Small Cell Lung Cancer
.
Cancer Discovery Editorial Office
American Association for Cancer Research | Publishing Division
615 Chestnut Street | 17th Floor | Philadelphia, PA 19106-4404
Phone: (215) 440-9300 | Fax: (215) 446-7297 | E-mail: cancerdiscovery@aacr.org